249 related articles for article (PubMed ID: 22210089)
1. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.
Colpo A; Hochberg E; Chen YB
Oncologist; 2012; 17(1):80-90. PubMed ID: 22210089
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
4. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW
Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
8. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
9. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
[TBL] [Abstract][Full Text] [Related]
10. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
Bentolila G; Pavlovsky A
Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
[TBL] [Abstract][Full Text] [Related]
11.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
12. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Shafey M; Duan Q; Russell J; Duggan P; Balogh A; Stewart DA
Leuk Lymphoma; 2012 Apr; 53(4):596-602. PubMed ID: 21929284
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
[TBL] [Abstract][Full Text] [Related]
14. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.
Isidori A; Piccaluga PP; Loscocco F; Guiducci B; Barulli S; Ricciardi T; Picardi P; Visani G
Expert Rev Hematol; 2013 Aug; 6(4):451-64. PubMed ID: 23991931
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
18. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
20. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]